RxDoctor Payments Data

Karen Dix, MD

Family Medicine · Long Beach, CANPI 1811920424

Payments from drug & device makers

$5,671in general payments, 2019–2025

Across 107 payments — averaging $53.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$478
  • Novo Nordisk$403
  • Edwards Lifesciences$290
  • Lilly USA, LLC$252
  • Boston Scientific$187
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$5,671100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,671 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$7,440
Medicare patients
27
Services billed
83

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban30$30,900
FarxigaDapagliflozin Propanediol21$24,073
JanuviaSitagliptin Phosphate16$18,912
JardianceEmpagliflozin12$17,392
OzempicSemaglutide14$15,720
Metformin Er GastricMetformin Hcl11$4,444
BreynaBudesonide/Formoterol Fumarate16$2,246
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,538
Albuterol Sulfate HfaAlbuterol Sulfate57$1,536
Atorvastatin Calcium220$1,525
Ventolin HfaAlbuterol Sulfate11$1,098
Amlodipine Besylate184$1,069
Levothyroxine Sodium76$1,026
Omeprazole77$1,014
Losartan Potassium89$906

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$30,90030 claims
AstraZenecaFarxiga$2,338$24,07321 claims
MerckJanuvia$178$18,91216 claims
Boehringer IngelheimJardiance$149$17,39212 claims
Novo NordiskOzempic$403$15,72014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →